Get the FREE Ultimate OpenClaw Setup Guide →

anxiety-screening

npx machina-cli add skill rhavekost/clinical-toolkit/anxiety-screening --openclaw
Files (1)
SKILL.md
11.2 KB

Anxiety Screening

Description

This skill helps administer and interpret validated anxiety screening instruments. The GAD-2 serves as a brief initial screener, while the GAD-7 provides comprehensive assessment of generalized anxiety severity.

Clinical Context: These tools help quantify anxiety symptoms, track treatment response, and support clinical decision-making. The GAD-7 also screens reasonably well for panic disorder, social anxiety, and PTSD. These are support tools that supplement, not replace, comprehensive clinical evaluation.

Quick Reference

Assessment Comparison

AssessmentItemsTimePurposeCutoffWhen to Use
GAD-22<1 minBrief screening≥3 → Full GAD-7Time-limited settings, universal screening
GAD-772-3 minSeverity assessment≥10 = Moderate+Comprehensive assessment, treatment monitoring

For detailed comparison: See references/screening-comparison.md

GAD-7 Severity Levels

ScoreSeverityFirst-Line TreatmentFollow-up
0-4MinimalMonitor, psychoeducationAnnual or as needed
5-9MildRelaxation/stress management2-4 weeks
10-14ModerateTherapy or medication2-4 weeks
15-21SevereCombination therapy, specialty referral1-2 weeks

For detailed severity interpretations: See references/severity-levels.md

For treatment recommendations: See references/clinical-decision-trees.md

Interactive Administration (Optional)

Use this mode when the clinician says "start" or "administer" the GAD-2/GAD-7.

  1. Confirm readiness and explain the past 2 weeks time frame plus the 0-3 response scale.
  2. Ask one item at a time (verbatim from the asset file) and wait for a response before continuing.
  3. Accept numeric or verbal responses; if unclear or out of range, ask for clarification.
  4. Record each response and keep a running total.
  5. If responses indicate severe anxiety or there is any safety concern, pause and assess safety (see Safety Considerations).
  6. After the final item, calculate the total score, interpret severity, and provide next-step guidance.
  7. Offer a brief documentation summary if requested.

Assessment Tools

GAD-7 (Generalized Anxiety Disorder-7)

Complete assessment with items, scoring, and documentation:assets/gad-7.md

Key Facts:

  • 7 items, 0-3 scale each, total score 0-21
  • Cutoff ≥10: 89% sensitivity/82% specificity for GAD
  • 5-point change: Indicates treatment response
  • Validated for screening GAD, panic, social anxiety, PTSD
  • Does NOT: Include safety item (screen for suicidal ideation with PHQ-9 if needed)

GAD-2 (Generalized Anxiety Disorder-2)

Complete assessment with items, scoring, and documentation:assets/gad-2.md

Key Facts:

  • 2 items (first 2 from GAD-7), 0-3 scale each, total score 0-6
  • Cutoff ≥3: Positive screen → administer full GAD-7
  • Use for: Rapid screening, universal screening in time-limited settings
  • Does NOT: Assess severity or screen for suicidal ideation

When to use GAD-2 vs GAD-7: See references/screening-comparison.md

Clinical Workflow

1. Choose Assessment

digraph assessment_selection {
    rankdir=LR;
    node [shape=box, style=rounded];

    start [label="Patient\nPresentation", shape=ellipse];
    time_check [label="Time-limited\nencounter?", shape=diamond];
    purpose_check [label="Treatment\nmonitoring?", shape=diamond];
    gad2 [label="Start with\nGAD-2", style="filled", fillcolor=lightblue];
    gad2_score [label="GAD-2\nscore ≥3?", shape=diamond];
    gad7 [label="Administer\nGAD-7", style="filled", fillcolor=lightgreen];
    monitor [label="Negative\nscreen", style="filled", fillcolor=gray90];

    start -> time_check;
    time_check -> gad2 [label="yes\n(primary care,\nER)"];
    time_check -> purpose_check [label="no"];
    purpose_check -> gad7 [label="yes"];
    purpose_check -> gad7 [label="no\n(suspected\nanxiety)"];
    gad2 -> gad2_score;
    gad2_score -> gad7 [label="yes"];
    gad2_score -> monitor [label="no"];
}

2. Administer Assessment

GAD-2: assets/gad-2.md - 2 items, <1 minute GAD-7: assets/gad-7.md - 7 items, 2-3 minutes

3. Score and Interpret

Scoring:

  • Sum all item responses
  • GAD-2: 0-6 range
  • GAD-7: 0-21 range

Interpretation:

4. Clinical Decision-Making

Follow clinical decision trees: references/clinical-decision-trees.md

General pathways:

  • GAD-7 0-4: Monitor, psychoeducation
  • GAD-7 5-9: Relaxation techniques, stress management, watchful waiting
  • GAD-7 10-14: Active treatment (CBT or medication)
  • GAD-7 15-21: Combination therapy, specialty referral

5. Document

Use documentation templates in:

Documentation standards: ../../docs/references/documentation-standards.md

Treatment Monitoring

Use GAD-7 to track progress:

  • Baseline: Administer at treatment start
  • Follow-up: Every 2-4 weeks during active treatment
  • Response indicators:
    • <5-point decrease: Minimal response (consider treatment change)
    • 5-9 point decrease: Partial response (continue, monitor)
    • ≥5-point decrease AND score <10: Good response
    • Score <5: Remission (treatment goal)

Do NOT use GAD-2 for treatment monitoring - insufficient detail

Safety Considerations

GAD-7 Does NOT Screen for Suicidal Ideation

Important: Unlike PHQ-9, GAD-7 has no safety item

When to assess suicidal ideation:

  • Severe anxiety (GAD-7 ≥15)
  • Co-occurring depression
  • Any clinical concern

How to assess:

Always assess:

  • Panic attacks and their impact
  • Avoidance behaviors affecting functioning
  • Substance use (especially self-medication)
  • Co-occurring depression (administer PHQ-9)

Crisis Resources:

  • 988 Suicide & Crisis Lifeline (call or text)
  • Crisis Text Line: Text HOME to 741741
  • Emergency: 911

Universal crisis protocols: ../../docs/references/crisis-protocols.md

Special Considerations

Differential Diagnosis

When GAD-7 is Elevated

digraph differential_diagnosis {
    rankdir=TB;
    node [shape=box, style=rounded];

    high_gad7 [label="GAD-7 ≥10", shape=ellipse, style="filled", fillcolor=yellow];
    assess_type [label="Assess Anxiety\nPresentation", style="filled", fillcolor=lightblue];

    chronic_worry [label="Chronic worry\nabout multiple\nthings?", shape=diamond];
    panic_attacks [label="Recurrent panic\nattacks?", shape=diamond];
    social_fears [label="Fear of social\nsituations?", shape=diamond];
    trauma_hx [label="Trauma\nhistory?", shape=diamond];

    gad [label="Likely GAD\n(Generalized\nAnxiety)", style="filled", fillcolor=lightgreen];
    panic [label="Likely\nPanic Disorder", style="filled", fillcolor=lightgreen];
    social [label="Likely Social\nAnxiety", style="filled", fillcolor=lightgreen];
    ptsd [label="Screen for\nPTSD", style="filled", fillcolor=orange];
    other [label="Consider:\n• Health anxiety\n• OCD\n• Medical causes", style="filled", fillcolor=lightyellow];

    further [label="Further\nClinical Assessment\nRequired", style="filled", fillcolor=lightblue];

    high_gad7 -> assess_type;
    assess_type -> chronic_worry;
    chronic_worry -> gad [label="yes"];
    chronic_worry -> panic_attacks [label="no"];
    panic_attacks -> panic [label="yes"];
    panic_attacks -> social_fears [label="no"];
    social_fears -> social [label="yes"];
    social_fears -> trauma_hx [label="no"];
    trauma_hx -> ptsd [label="yes"];
    trauma_hx -> other [label="no"];

    gad -> further;
    panic -> further;
    social -> further;
    ptsd -> further;
    other -> further;
}

Note: GAD-7 screens for anxiety severity but does not differentiate specific disorders. Further clinical assessment required for diagnosis.

  • Medical causes: Rule out hyperthyroidism, cardiac arrhythmias, respiratory conditions, caffeine/substances, medication side effects
  • Co-occurring depression: Very common (60% overlap)—administer both GAD-7 and PHQ-9, integrated treatment
  • Substance use: May be self-medication; substances worsen anxiety; withdrawal causes anxiety
  • Cultural factors: Expression varies across cultures; use validated versions
  • Age: Validated for teens (12+) and older adults; different tools for children <12

Referral Guidelines

When to Refer to Specialty Mental Health

Immediate/Urgent:

  • GAD-7 ≥15 at initial presentation
  • Severe functional impairment
  • Inadequate response to initial treatment
  • Patient request for specialty care

Routine:

  • GAD-7 10-14 if patient prefers specialist
  • Complex presentation (trauma, substance use)
  • Need for specialized anxiety treatment (exposure therapy, etc.)

Complete referral guidance: ../../docs/references/referral-guidelines.md

Limitations

Screening tools, not diagnostic instruments. Do not replace clinical assessment; do not differentiate specific anxiety disorders. Clinical judgment supersedes scores. Potential issues: false positives (medical conditions, substances), false negatives (minimization), cultural/linguistic factors.

Usage Examples

Example requests: "Administer GAD-7", "Screen for anxiety", "Score GAD-7", "Treatment for score 17", "Screen anxiety and depression together?"

References

Primary Literature:

  • Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097.
  • Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317-325.

Clinical Guidelines:

  • Bandelow B, et al. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93-107.
  • Katzman MA, et al. Canadian clinical practice guidelines for the management of anxiety. BMC Psychiatry. 2014;14 Suppl 1:S1.

No copyright restrictions - GAD-2 and GAD-7 are freely available for clinical and research use

Source

git clone https://github.com/rhavekost/clinical-toolkit/blob/main/dist/consumer/claude/anxiety-screening/SKILL.mdView on GitHub

Overview

This skill administers and interprets validated anxiety tools to quantify symptoms and guide care. It uses the brief GAD-2 for rapid screening and the full GAD-7 for severity assessment, supporting treatment monitoring and clinical decisions. It also notes that GAD-7 can help screen for panic, social anxiety, and PTSD, while not replacing comprehensive evaluation.

How This Skill Works

Clinicians start with the GAD-2 for quick screening (<1 minute). If the GAD-2 score is 3 or higher, they administer the GAD-7 (2-3 minutes) to assess severity (0-21) and guide next steps. Scores are recorded, interpreted against cutoffs, and used to inform treatment decisions and follow-up, with safety considerations applied if needed.

When to Use It

  • Time-limited settings or universal screening using GAD-2.
  • Comprehensive assessment or ongoing treatment monitoring with GAD-7.
  • Differentiating anxiety disorders, noting that GAD-7 also screens for related conditions (panic, social anxiety, PTSD).
  • Assessing treatment response via score changes (e.g., a 5-point change indicates response).
  • When patients report overwhelming fear or avoidance behaviors that require quantification.

Quick Start

  1. Step 1: Confirm the patient understands the 2-week window and the 0-3 response scale.
  2. Step 2: Administer items one at a time, recording each response verbatim from the asset file.
  3. Step 3: Calculate the total score, interpret severity, and determine next steps or documentation.

Best Practices

  • Start with GAD-2 in time-limited or universal screening to flag potential anxiety symptoms.
  • If GAD-2 ≥ 3, administer the full GAD-7 for a comprehensive severity assessment.
  • Use established cutoffs: GAD-2 ≥ 3; GAD-7 ≥ 10 indicates moderate+ severity.
  • Document total scores, track changes over time, and interpret within the clinical context.
  • Remember these tools supplement, not replace, a full clinical evaluation and safety assessment if indicated.

Example Use Cases

  • Primary care clinic screens adults with GAD-2; positives proceed to GAD-7 for severity and management planning.
  • Mental health specialty clinic uses GAD-7 to monitor treatment response over 6-8 weeks of therapy.
  • Urgent care evaluates acute anxiety symptoms; GAD-2 provides rapid screening, followed by GAD-7 if needed.
  • Workplace health program implements universal screening with GAD-2 to identify individuals needing further evaluation.
  • Psychiatry intake uses GAD-7 to assess anxiety and screens for related disorders (panic, social anxiety, PTSD) as part of a broader assessment.

Frequently Asked Questions

Add this skill to your agents
Sponsor this space

Reach thousands of developers